课件：陆劲松 乳腺癌的内分泌治疗进展 last02 07 print.ppt

* * TEAM研究，随访2.75年（33个月），在总治疗人群中，降低11%的疾病复发风险。 * TEAM研究，随访2.75年（33个月），在接受治疗的人群中（去除没有接受治疗的96例患者），降低17%的疾病复发风险。 * TEAM研究，随访2.75年（33个月），在总治疗人群中，降低19%的远处转移风险。 * SPEAKER’S NOTES: This slide summarizes the study design and follow-up for the mature results of the IES trial. IES was designed to evaluate whether patients who remained disease-free after 2 to 3 years of tamoxifen were more effectively treated by switching to exemestane than by continuing tamoxifen for the remainder of their 5 year treatment. Median follow-up for the trial is 56 months. Patients were followed up for more than 2 years after the discontinuation treatment. Currently, more than 99% of patients have completed their study treatment. There were more than 5,000 patient years on treatment for exemestane and for tamoxifen. Over 10,000 patient years were included in post treatment follow-up. Reference 1. Coombes, et al. First mature survival analysis of the Intergroup Exemestane Study: a randomized trial in disease-free, postmenopausal patients with early breast cancer randomized to continue tamoxifen or switch to exemestane following an initial 2 to 3 years of adjuvant tamoxifen. Presented at: American Society of Clinical Oncologists (ASCO) Annual Meeting; June 2-6, 2006; Atlanta, GA, USA. * SPEAKER’S NOTES This slide shows disease free survival (DFS) data in the ER positive and unknown population of the IES trial. The shaded bar indicates treatment completion at 2 to 3 years. DFS was significantly better in the exemestane group versus the tamoxifen group. A 25% improvement in the probability of DFS was seen with exemestane. The absolute difference between tamoxifen and exemestane at 2.5 years was 3.4%. This benefit was maintained after the end of treatment, with a 3.5% absolute benefit at 5 years of follow-up. Reference 1. Coombes, et al. First mature survival analysis of the Intergroup Exemestane Study: a randomized trial in disease-free, postmenopausal patients with early breast cancer randomize